Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Repositioning Axon Enterprise (A)
McBrady, Matthew; Sesia, AldoCaso DARDEN-F-2003-EFinanzasIn November 2017, Axon Enterprise, Inc. (Axon), was amid transforming from a simple manufacturing company focused almost exclusively on its market leading TASER-brand conducted energy weapons (CEWs) for law enforcement into a multiline, technology-driven provider of low margin body-worn cameras (BWCs) and unproven cloud-based enterprise software and connected devices. The company’s stock had languished for years, and the market did not seem to un...Desde 8,20 €
-
NatuRi Corporation
Higgins, Robert F.; Fuller, Virginia A.Caso HBS-807027-EFinanzasNatuRi Corp. was a start up, founded in 2005, aiming to manufacture a cholesterol-lowering drug made from the byproducts of rice bran oil production. With operations split between Chennai, India and Boston, Massachusetts, NatuRi faced several challenges, including securing funding for the organization. NatuRi had captured the attention of at least four potential investors willing to offer an investment. Its managers were challenged to weigh their...Desde 8,20 €
-
Repositioning Axon Enterprise (B): Financing the Future of Police Reform
McBrady, Matthew; Sesia, AldoCaso DARDEN-F-2004-EFinanzasThis case on Axon Enterprise, Inc. (Axon), highlights what the company’s CFO and head of investor relations told attendees at Axon’s Investor Day in November 2017. It also describes a follow-on offering in May 2018, and that by the end of 2020 the company could be in its weakest cash position in several years. In 2020, the CFO believed the company needed between $250 million and $350 million to fund the business moving forward. He needed to weigh...Desde 5,74 €
-
U.S. Food and Drug Administration
Higgins, Robert F.; Hamermesh, Richard G.; Fuller, Virginia A.Caso HBS-807050-ELiderazgo y Dirección de personasDescribes the U.S. FDA with particular emphasis on its role in the development of new drugs, biologic products, and medical devices today. Provides context for the drug approval process by describing the FDA's history and organizational structure.Desde 8,20 €
-
Odyssey Healthcare
Higgins, Robert F.; Fuller, Virginia A.; Raffat, UmerCaso HBS-809052-EIniciativa emprendedoraIn January 2001, Dick Burnham, CEO of Odyssey Healthcare, and Odyssey's Board of Directors were considering selling the hospice care company to a larger provider or making an initial public offering (IPO). With 38 hospice locations in 21 states, Odyssey had been providing care to the terminally ill since its first location opened in 1996. Since then, the company had grown rapidly through a series of acquisitions, development of new hospice locati...Desde 8,20 €